Heart Disease News and Research

Latest Heart Disease News and Research

Gilead, CRF commence ranolazine Phase 3 clinical trial for chronic stable angina in post-PCI setting

Gilead Sciences, Inc. and the Cardiovascular Research Foundation (CRF) today announced the initiation of RIVER-PCI (Ranolazine for Incomplete VEssel Revascularization post-PCI), a Phase 3 clinical trial evaluating the utility of ranolazine to prevent major adverse cardiovascular events (MACE) in patients with a history of chronic angina who have incomplete revascularization following percutaneous coronary intervention (PCI).

7 Nov 2011

Groups sound off on exchanges as governors wrestle with HHS over control

The issue of shaping health insurance exchanges is raising controversy even as states worry they'll bear the brunt of the public's anger over the law.

7 Nov 2011

Medtronic CoreValve System for direct aortic and subclavian implantation receives CE Mark

Medtronic, Inc. today announced it has received CE Mark for the Medtronic CoreValve System to be delivered using direct aortic access.

From Medtronic 7 Nov 2011

Mediterranean Diet beneficial even without weight loss

The benefits of the Mediterranean Diet go beyond weight loss, even when weight loss isn't achieved. Researchers from St. Vincent's Hospital, Melbourne, studied 12 patients without diabetes who had nonalcoholic fatty liver disease (NAFLD), and the results of their study demonstrated that liver health was improved even without weight loss.

7 Nov 2011

NewCardio's automated cardiac safety solution selected by top pharma company for Phase I drug study

NewCardio, Inc., a cardiovascular diagnostic solutions developer, announced today that a top 5 global pharmaceutical company has selected QTinno, their automated cardiac safety solution, for an upcoming Phase I drug safety study.

7 Nov 2011

Transgenomic and A. Menarini Diagnostics enter distribution agreement for mutation detection systems

Transgenomic, Inc. and A. Menarini Diagnostics today announced an exclusive distribution agreement for Transgenomic's SURVEYOR Scan and WAVE MCE (Micro-Capillary Electrophoresis) Mutation Detection system to its network of over 2,000 pathologists throughout Europe.

7 Nov 2011

Pharmacyclics first quarter GAAP net loss increases to $14.5M

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal first quarter ended September 30, 2011.

7 Nov 2011

Thoratec board authorizes repurchase of additional $50M of common stock

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that its Board of Directors has authorized the repurchase of an additional $50 million of the company's shares of common stock over the next year.

7 Nov 2011

InfraReDx TVC Imaging System to be exhibited at TCT 2011

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced that its TVC Imaging System for the true vessel characterization of coronary artery disease will be highlighted during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2011).

7 Nov 2011

DuoCort Pharma granted marketing authorization for adrenal insufficiency drug, Plenadren in Europe

The Swedish specialty pharma company, DuoCort Pharma, announced today that the European Commission has granted a European Marketing Authorisation for Plenadren (hydrocortisone, modified release tablet), an orphan drug for treatment of adrenal insufficiency in adults, bringing these patients their first pharmaceutical innovation in over 50 years.

7 Nov 2011

InfraReDx launches enhanced version of LipiScan IVUS Coronary Imaging System

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced the launch of its TVC Imaging System, an enhanced version of the LipiScan IVUS Coronary Imaging System.

7 Nov 2011

MILV subsidiary acquires formula to restore proper kidney function

Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. announced that it has executed the formal closing documents and acquired the chronic kidney disease formula. This formula was developed to restore proper kidney function.

7 Nov 2011

Toshiba to showcase new 56-inch LCD monitor for Infinix-i line at TCT 2011

In cath lab procedures, clearly visualizing complex vascular structures is crucial to making exams faster and easier. Toshiba will showcase a new 56-inch LCD monitor for the Infinix-i line at this year's Transcatheter Cardiovascular Therapeutics (TCT) annual conference, November 7-11, 2011, in San Francisco, Calif.

7 Nov 2011

ISET 2012 to discuss latest advances in chronic cerebrospinal venous insufficiency

Innovators in the field of endovascular therapy will explore the often-contentious topic of chronic cerebrospinal venous insufficiency (CCSVI), which is theorized to be a contributing factor in the development of multiple sclerosis (MS), at the 24th annual International Symposium on Endovascular Therapy.

7 Nov 2011

Abbott announces results from HUMIRA Phase 3 study on axSpA

Abbott today announced results from the Phase 3 ABILITY-1 study of HUMIRA (adalimumab) in patients with active non-radiographic axial spondyloarthritis.

7 Nov 2011

Scientists achieve major step toward goal of producing synthetic Taxol

Taxanes are a family of compounds that includes one of the most important cancer drugs ever discovered, Taxol, among other cancer treatments. But the difficulty producing these complex molecules in the lab has hampered or blocked exploration of the family for further drug leads. Now, a group of Scripps Research Institute scientists has successfully achieved a major step toward the goal of synthetically producing Taxol and other complex taxanes on a quest to harness chemical reactions that could enable research on previously unavailable potential drugs.

7 Nov 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

Getinge receives FTC approval to acquire Atrium Medical

Getinge has been granted the approval of US anti-trust authority FTC (Federal Trade Commission) to go ahead with the acquisition of Atrium Medical Inc. The acquisition was finalized on 4 November, 2011, and will be consolidated in Getinge's accounts as of 1 November this year.

7 Nov 2011

Dual imaging approach could improve diagnosis, treatment of coronary artery disease

A new device that combines two microimaging technologies can reveal both the detailed anatomy of arterial linings and biological activities that, in coronary arteries, could indicate the risk of heart attacks or the formation of clots in arterial stents.

7 Nov 2011

New study questions effectiveness of current exercise referral schemes

Research commissioned by the NIHR Health Technology Assessment programme and carried out by research teams from the Peninsula College of Medicine and Dentistry (PCMD) and the Universities of Exeter (Sport and Health Sciences) and Brunel (Health Economics Research Group), has called into question the effectiveness of exercise referral schemes as they are delivered at present.

7 Nov 2011